Next Article in Journal
Mitoxantrone-Surfactant Interactions: A Physicochemical Overview
Next Article in Special Issue
Development of a Topical Resveratrol Formulation for Commercial Applications Using Dendrimer Nanotechnology
Previous Article in Journal
Chemical Components and Pharmacological Activities of Terpene Natural Products from the Genus Paeonia
Previous Article in Special Issue
Biotransformation of Resveratrol: New Prenylated trans-Resveratrol Synthesized by Aspergillus sp. SCSIOW2
Article Menu
Issue 10 (October) cover image

Export Article

Open AccessArticle
Molecules 2016, 21(10), 1341; doi:10.3390/molecules21101341

Resveratrol Ameliorates the Depressive-Like Behaviors and Metabolic Abnormalities Induced by Chronic Corticosterone Injection

College of Pharmacy, Henan University of Traditional Chinese Medicine, Zhengzhou 450046, China
*
Authors to whom correspondence should be addressed.
Academic Editor: Thomas J. Schmidt
Received: 14 June 2016 / Revised: 24 September 2016 / Accepted: 6 October 2016 / Published: 13 October 2016
(This article belongs to the Special Issue Improvements for Resveratrol Efficacy)
View Full-Text   |   Download PDF [1869 KB, uploaded 13 October 2016]   |  

Abstract

Chronic glucocorticoid exposure is known to cause depression and metabolic disorders. It is critical to improve abnormal metabolic status as well as depressive-like behaviors in patients with long-term glucocorticoid therapy. This study aimed to investigate the effects of resveratrol on the depressive-like behaviors and metabolic abnormalities induced by chronic corticosterone injection. Male ICR mice were administrated corticosterone (40 mg/kg) by subcutaneous injection for three weeks. Resveratrol (50 and 100 mg/kg), fluoxetine (20 mg/kg) and pioglitazone (10 mg/kg) were given by oral gavage 30 min prior to corticosterone administration. The behavioral tests showed that resveratrol significantly reversed the depressive-like behaviors induced by corticosterone, including the reduced sucrose preference and increased immobility time in the forced swimming test. Moreover, resveratrol also increased the secretion of insulin, reduced serum level of glucose and improved blood lipid profiles in corticosterone-treated mice without affecting normal mice. However, fluoxetine only reverse depressive-like behaviors, and pioglitazone only prevent the dyslipidemia induced by corticosterone. Furthermore, resveratrol and pioglitazone decreased serum level of glucagon and corticosterone. The present results indicated that resveratrol can ameliorate depressive-like behaviors and metabolic abnormalities induced by corticosterone, which suggested that the multiple effects of resveratrol could be beneficial for patients with depression and/or metabolic syndrome associated with long-term glucocorticoid therapy. View Full-Text
Keywords: resveratrol; corticosterone; depression; metabolic abnormalities resveratrol; corticosterone; depression; metabolic abnormalities
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Li, Y.-C.; Liu, Y.-M.; Shen, J.-D.; Chen, J.-J.; Pei, Y.-Y.; Fang, X.-Y. Resveratrol Ameliorates the Depressive-Like Behaviors and Metabolic Abnormalities Induced by Chronic Corticosterone Injection. Molecules 2016, 21, 1341.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top